Vecuronium Inhibitors
1 drugsAbout Vecuronium
Vecuronium is a neuromuscular blocking agent. It functions by competitively binding to acetylcholine receptors at the neuromuscular junction, preventing depolarization and causing muscle relaxation.
Vecuronium is a therapeutic target to induce muscle relaxation, primarily during surgical procedures. There is currently no genetic evidence directly linking Vecuronium to specific diseases.
Vecuronium is targeted by one FDA-approved drug, BRIDION (sugammadex), a small molecule developed by Merck. BRIDION was first approved in 2015 and is used in 'Other' therapeutic areas.
Top Vecuronium Drugs
Merck is the only company with an approved drug targeting Vecuronium.
Low competition suggests high barriers to entry or limited market potential.
Vecuronium Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Vecuronium, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel biologics.
Vecuronium Clinical Trials 106 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Vecuronium. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 3 | 3 | 0 | 50% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
| Phase 3 | 20 | 19 | 0 | 1 | 100% |
| Phase 4 | 76 | 64 | 9 | 3 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Vecuronium Drug Approval Timeline (2015 - 2015)
BRIDION was approved in 2015 and remains the only approved drug.
The single approval and lack of subsequent drugs indicates a potentially saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 73 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Vecuronium. A trial counts if an approved drug acting on Vecuronium is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.